Albertsons Agrees to $774 Million Opioid Settlement, Colorado to Receive $32 Million

Albertsons Companies has agreed to pay nearly $774 million to resolve all opioid-related claims against the grocery chain, marking one of the final major retailer settlements in the sprawling litigation that has reshaped how pharmacies operate nationwide. Colorado will receive at least $32 million from the agreement, pushing the state's total opioid settlement recovery past $912 million.

The settlement, announced Tuesday by Colorado Attorney General Phil Weiser alongside attorneys general from California, Illinois, and Oregon, resolves years of litigation alleging that Albertsons and its pharmacy operations failed to implement adequate safeguards against the improper distribution of prescription opioids. The company operates nearly 100 Safeway and Albertsons locations across Colorado.

"They were pushing out opioids, fueling an addiction crisis, when they could and should have been asking an important question: why are all these people getting so many opioids?" Weiser told Denver7. "They didn't ask those questions. Many people were not asking questions. They were just cashing checks. Now these companies are being held to account. Now we have money to invest in treatment recovery to address this crisis."

The Settlement Structure

The $773.7 million national agreement will be paid out over nine years, a timeline that allows Albertsons to absorb the financial impact while continuing operations. The company recorded a $600 million charge in its most recent quarter, net of tax, resulting in a reported loss of roughly $480 million. Albertsons shares fell as much as 4.8% following the announcement.

In a statement, Albertsons characterized the settlement as "a step toward resolving opioid-related litigation" while emphasizing that the agreement constitutes "not an admission of wrongdoing or liability." The company pointed to its existing pharmacy practices, noting that it has "invested in strong pharmacy practices designed to promote the safe and appropriate use of prescription medications" and expressing pride in its pharmacists' "long-standing role in promoting responsible medication use."

The settlement covers all opioid-related claims against Albertsons Companies, including those brought by states, local governments, and tribal nations. However, the agreement does not resolve ongoing negotiations over injunctive relief—court-ordered changes to business practices designed to prevent future misconduct.

According to the Colorado Attorney General's office, "important negotiations with respect to injunctive relief continue." These discussions could result in mandated changes to Albertsons' pharmacy operations, including enhanced monitoring systems, prescriber education requirements, or restrictions on certain dispensing practices.

Colorado's Growing Recovery

The Albertsons settlement brings Colorado's total opioid settlement recovery to more than $912 million, a figure that reflects years of coordinated litigation by the Attorney General's office against manufacturers, distributors, and pharmacies found to have contributed to the state's opioid crisis.

Colorado has already reached similar settlements with Kroger—which operates King Soopers and City Market locations in the state—as well as Walgreens, CVS, Walmart, Johnson & Johnson, and major drug distributors including McKesson, Cardinal Health, and AmerisourceBergen. Each settlement has added to a growing fund intended to address the public health consequences of the opioid epidemic.

The $32 million Colorado will receive from Albertsons represents approximately 4% of the national settlement, roughly proportional to the state's population and the documented impact of the opioid crisis within its borders. Colorado has experienced overdose death rates above the national average in recent years, with fentanyl now driving the majority of fatal overdoses.

How Settlement Funds Flow

Colorado's opioid settlement funds are distributed through a structured allocation system designed to balance state oversight with local decision-making. The majority—60%—flows to regional councils that determine how to deploy resources within their jurisdictions, subject to oversight from the state's Opioid Abatement Council.

Local governments receive a 20% share directly, providing counties and municipalities with flexible funding for programs tailored to their specific needs. The state retains 10% for statewide initiatives, while the remaining 10% supports infrastructure projects that expand treatment capacity.

This distribution model reflects lessons learned from earlier tobacco settlements, where funds were sometimes diverted to general budget purposes rather than directed toward public health interventions. Colorado's framework requires that settlement dollars be spent on opioid abatement activities, including prevention, treatment, harm reduction, and recovery support services.

Regional councils have funded naloxone distribution programs, expanded medication-assisted treatment capacity in underserved areas, supported peer recovery specialist training, and invested in housing assistance for individuals in recovery. The Albertsons settlement will extend these programs while potentially allowing for new initiatives as the funding stream continues through the early 2030s.

The Retailer Reckoning

Albertsons' settlement follows similar agreements reached by other major retailers over the past three years, collectively representing more than $17 billion in national payouts. CVS Health, Walmart, and Walgreens agreed to settlements totaling more than $13 billion in late 2022. Kroger reached a $1.2 billion agreement with states and subdivisions in 2023, plus an additional $36 million to Native American tribes.

These settlements have fundamentally altered the pharmacy landscape. Retailers have implemented enhanced prescription monitoring systems, reduced dispensing of high-dose opioid formulations, and increased training for pharmacists on recognizing suspicious prescribing patterns. Some chains have exited the opioid dispensing business entirely in certain markets.

The litigation has also produced changes at the regulatory level. The Drug Enforcement Administration has tightened enforcement against pharmacies with unusual dispensing patterns, while state pharmacy boards have revised standards of care to emphasize the responsibility of pharmacists to verify the legitimacy of prescriptions.

For individuals and families affected by opioid addiction, the settlements represent a form of accountability that was elusive for years as the crisis escalated. While no amount of money can reverse the damage caused by the epidemic, the funds are supporting expanded access to treatment and prevention programs that may prevent future cases of addiction.

Looking Ahead

With Albertsons now joining the roster of settled defendants, attention turns to the remaining holdouts and the ongoing negotiations over injunctive relief. The settlement agreements include provisions requiring pharmacies to maintain enhanced monitoring systems and cooperate with state prescription drug monitoring programs, but advocates have pushed for more comprehensive reforms.

Colorado's Opioid Abatement Council continues to refine its funding priorities as the settlement dollars flow in. Recent allocations have emphasized equity considerations, directing resources toward communities that have experienced disproportionate overdose death rates, including rural areas with limited treatment infrastructure and communities of color where the crisis has intensified in recent years.

The $912 million total represents a significant investment in Colorado's response to the opioid crisis, though public health experts caution that sustained funding will be necessary to address a problem that has developed over decades. The multi-year structure of the settlements provides some predictability, but state officials are already considering how to maintain programs once settlement funds expire in the 2030s.

For now, the Albertsons settlement adds another chapter to Colorado's ongoing effort to transform litigation victories into tangible public health improvements. As Attorney General Weiser noted, the question that defendants failed to ask—why so many people were receiving so many opioids—continues to guide the state's approach to preventing similar crises in the future.